Trigeminal Nerve Stimulation in Treatment-resistant Generalized Anxiety Disorder: a Feasibility Study
Recruiting now · Not applicable
Conditions studied: Generalized Anxiety Disorder
In brief
This is a feasibility study for trigeminal nerve stimulation (TNS) in patients with treatment-resistant generalized anxiety disorder (TR-GAD). Ten participants will receive TNS for 8 weeks as an augmentation strategy to pharmacological treatment for generalized anxiety disorder (GAD). * The primary objective is to ascertain if TNS is a safe and well-tolerated treatment for patients with TR-GAD. * The secondary objective will be to monitor changes in GAD symptom severity throughout the study. Results from this study will inform a randomized controlled trial to be conducted in the future.
Key facts
- Study ID
- NCT06278909
- Run by
- Dr. Rafael Freire
- People needed
- 10
- Starts
- 2024-01-18
- Expected to finish
- 2026-04-01
- Last updated by the study team
- 2025-04-08
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5) criteria for generalized anxiety disorder.
- Subjects on a stable dose of an selective serotonin reuptake inhibitor (SSRI) or serotonin and noradrenaline reuptake inhibitor (SNRI) for at least 8 weeks.
- Treatment-resistant - treatment resistance will be defined as lack of response to at least two drugs, from two different classes of drugs considered first-line or second-line for GAD. Only trials lasting at least 8 weeks, and with at least the minimum effective dose of the given medication will be considered failed trials.
You may not qualify if…
- Moderate to severe major depressive disorder
- Moderate to high suicidality
- Diagnosis of obsessive compulsive disorder (OCD), PTSD, bipolar disorder, schizophrenia, schizoaffective disorder, personality disorders, substance use disorders, intellectual disabilities and dementia or other neurological diseases including trigeminal neuralgia
- Pregnant or breastfeeding women
- Participants who are experiencing seizures
- Implanted vagal nerve stimulation (VNS) or other electrical devices
- Participants who are already undergoing transcutaneous electrical nerve stimulation
- Consumption of cannabis, any cannabis by-products, illicit drugs, or alcohol above 3 drinks per week
- Consumption of natural health products that may affect anxiety or depression symptoms
Where it is running
- Kingston Health Sciences Centre — Kingston, Ontario, Canada (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.